Evidence map›Paper›PMID 30711119›Full record

SynthesisMayo Clinic proceedings2019

Effect of Exercise and Pharmacological Interventions on Visceral Adiposity: A Systematic Review and Meta-analysis of Long-term Randomized Controlled Trials.

Shreya Rao, Ambarish Pandey, Sushil Garg, Bryan Park, Helen Mayo, Jean-Pierre Després, Dharam Kumbhani, James A de Lemos, Ian J Neeland

Open access · greenAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Mayo Clinic proceedings, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Investigating the Pathogenesis and Treatment of Type 2 Diabetes from the Perspective of Adipose Tissue.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Review
  17. Review
  18. Metabolic syndrome.Nature reviews. Disease primers · 2024
    Review
  19. Weight Gain and Antiretroviral Therapy.Infectious disease clinics of North America · 2024
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Shreya RaoDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
Ambarish PandeyDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
Sushil GargDepartment of Internal Medicine, University of Minnesota Medical Center, Minneapolis.
Bryan ParkDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
Helen MayoHealth Sciences Digital Library and Learning Center, University of Texas Southwestern Medical Center, Dallas.
Jean-Pierre DesprésQuébec Heart and Lung Institute, Université Laval, Quebec, Canada.
Dharam KumbhaniDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
James A de LemosDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
Ian J NeelandDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas; Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas. Electronic address: ian.neeland@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USUniversité Laval · CAUniversity of Minnesota Medical Center · US

Funding

Visceral Adiposity and Diabetes: Translating Form to Function Using ImagingK23DK106520 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI NEELAND, IAN JASON · 2015 to 2019
$776k
NIDDK NIH HHS K23 DK106520
6 · The paper itself

Abstract

objectiveTo assess the effectiveness of exercise and pharmacotherapy interventions in reducing visceral adipose tissue (VAT). PATIENTS AND

methodsA systematic search of Ovid MEDLINE, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov, New York Academy of Science Grey Literature Report, and OpenGrey was combined with hand searches of existing literature. A total of 2515 titles and abstracts were reviewed. Only randomized controlled trials evaluating the effectiveness of monitored exercise or pharmacological interventions in reducing VAT by using computed tomography or magnetic resonance imaging during a sustained intervention period (≥6 months) were included. Data were independently extracted by reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and assessed for quality and risk of bias. Separate analyses for each intervention were performed using random effect models, with pooled estimates of the change in VAT area (in centimeters squared) from baseline to follow-up reported as standardized mean difference (SMD; with 95% CI).

resultsA total of 3602 participants from 17 randomized controlled trials were included in the final analysis. Both exercise and pharmacological interventions were associated with significant reductions in VAT: small reduction with pharmacological interventions (SMD, -0.27; 95% CI, -0.47 to -0.07; P=.02) and more substantial reductions with exercise interventions (SMD, -0.54; 95% CI, -0.63 to -0.46; P<.001). The mean absolute VAT reduction was greater in pharmacological trials than in exercise trials. Meta-regression exhibited a linear correlation between VAT and weight loss (R

conclusionExercise interventions resulted in greater reduction in VAT relative to weight loss than did pharmacological interventions. A preferential reduction in VAT may be clinically meaningful when monitoring success of interventions because weight loss alone may underestimate benefits.

Indexed as

Obesity, AbdominalAdiposityAnticholesteremic AgentsExerciseExercise TherapyHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsQuality of LifeRandomized Controlled Trials as TopicWeight LossAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic Agents

Identifiers

PMID30711119
PMCPMC6410710
OpenAlexW2914711689

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.